When was eGenesis founded?

eGenesis was founded in 2015 and raised its 1st funding round 1 year after it was founded.

Where is eGenesis located?

eGenesis is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts.

How many employees does eGenesis have?

As of May 31, 2026, the latest employee count at eGenesis is 151.

Is eGenesis a funded company?

eGenesis is a funded company, having raised a total of $481M across 6 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 22, 2016.

When was the latest funding round of eGenesis?

eGenesis' latest funding was a $***** Series D round on Sep 04, 2024, with participation from 11 investors.

Where does eGenesis rank among its competitors?

eGenesis ranks 2nd amongst 116 active competitors, of which 59 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Kytopen, which secured an undisclosed amount in Apr, 2026.

Who are the top competitors of eGenesis?

eGenesis' top competitors include Beam Therapeutics, Mammoth and Metagenomi. Among them, Kytopen secured the most recent funding round in April, 2026.

eGenesis - 2026 Company Profile, Team, Funding & Competitors

eGenesis is a series D company based in Cambridge (United States), founded in 2015 by Luhan Yang. It operates as a Developer of a gene transplantation platform for humanizing pig cells. eGenesis has raised $481M in funding from investors like Polaris Partners, Lux Capital and Farallon Capital Management. The company has 116 active competitors, including 59 funded and 12 that have exited. Its top competitors include companies like Beam Therapeutics, Mammoth and Metagenomi.

Company Details

Developer of a gene transplantation platform for humanizing pig cells. The company has developed a technology to humanize pig cells that will grow into human-compatible organs. These organs will be harvested in the donor pig and safely transplanted to human patients. The company's technology is based on the next-generation genome engineering toolset and CRISPR.

Website: egenesisbio.com
Social
Email ID: *****@egenesisbio.com
Registered Address: Cambridge, Massachusetts

Key Metrics

Founded Year

2015

Location

Cambridge, United States

Stage

Series D

Total Funding

$481M in 6 rounds

Latest Funding Round

Series D, Sep 04, 2024, $*****

Investors

Polaris Partners & 31 more

Ranked

2^nd among 116 active competitors

Employee Count

151 as on May 31, 2026

Investment & Acquisitions

ICBiotec

Similar Companies

Beam Therapeutics & 131 more

View eGenesis' full profile

eGenesis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Egenesis, Inc. CIN: 475370912 , United States, Active	Dec 31, 2014	-	100 (As on Dec 31, 2024)	-

eGenesis has raised a total funding of $481M over 6 rounds. Its first funding round was on Aug 22, 2016. Its latest funding round was a Series D round on Sep 04, 2024 for $*****. 11 investors participated in its latest round. eGenesis has 32 institutional investors.

Here is the list of recent funding rounds of eGenesis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 04, 2024	1479002	Series D	5615504	8763963	9822188	9283007
Feb 13, 2024	3567983	Series C	6475761	2889784	2505789	6231548
Mar 02, 2021	6714717	Series C	6207131	8092345	Farallon Capital Management & 11 more	Wellington Partners Venture Capital & 5 more

Access funding benchmarks and valuations. Sign up today!

View details of eGenesis's funding rounds and investors

The founders of eGenesis is Luhan Yang. Michael Curtis is the CEO of eGenesis.

Here are the details of eGenesis' key team members:

Luhan Yang: Co-Founder of eGenesis.
Contact Info: 1 email address

View details of eGenesis's Founder profiles and Board Members

eGenesis' employee count trend

eGenesis has 151 employees as of May 26. Here is eGenesis's employee count trend over the years:

Uncover eGenesis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of eGenesis include Beam Therapeutics, Mammoth and Metagenomi. Here is the list of Top 10 competitors of eGenesis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	Redmile Group, Google Ventures & 16 others	71/100
2nd	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$481M	Samsara BioCapital, Farallon Capital Management ... & 30 others	65/100
3rd	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, Decheng Capital & 34 others	65/100
4th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, RA Capital Management & 22 others	65/100
5th	Tessera Therapeutics 2017, Cambridge (United States), Series C	Provider of new genome engineering technology for treating multiple diseases	$610M	ADIA, Temasek & 22 others	64/100
6th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Viking Global Investors, Artis Ventures & 13 others	64/100
7th	Prime Medicine 2019, Cambridge (United States), Public	Developer of genetic therapies for a wide range of diseases	$315M	Samsara BioCapital, Casdin Capital & 10 others	64/100
8th	Kytopen 2017, Cambridge (United States), Series B	Developer of gene delivery systems for cell therapy	$44.5M	Northpond Ventures, Horizons Ventures & 11 others	61/100
9th	Scribe Therapeutics 2018, Alameda (United States), Series B	Developer of a gene-editing platform using CRISPR technology	$120M	Avoro Capital, Andreessen Horowitz & 6 others	61/100
10th	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Decheng Capital, Eclipse	60/100